CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
about
Elevated Pre-Antiretroviral Therapy CD39+CD8+ T Cell Frequency Is Associated With Early Mortality in Advanced Human Immunodeficiency Virus/Tuberculosis Co-infection.Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.Unfolding Role of a Danger Molecule Adenosine Signaling in Modulation of Microbial Infection and Host Cell Response.Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?Targeting adenosine for cancer immunotherapy.
P2860
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
@ast
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
@en
type
label
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
@ast
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
@en
prefLabel
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
@ast
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
@en
P2093
P2860
P1476
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
@en
P2093
Abel Bermudez
Belinda Cairns
Edward H van der Horst
Gregory M Hayes
Jan-Willem Theunissen
Karl J Schweighofer
Lawrence Chinn
Mark R Flory
Myra Perez
Sindy Liao-Chan
P2860
P304
P407
P577
2015-06-15T00:00:00Z